|
Immunome, Inc. (IMNM): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Immunome, Inc. (IMNM) Bundle
In the cutting-edge world of precision immunotherapies, Immunome, Inc. (IMNM) emerges as a groundbreaking biopharmaceutical company poised to revolutionize cancer and autoimmune disease treatment. With its innovative RecognImmune technology platform and lead drug candidate IMM-BCP-01 for breast cancer, this Horsham, Pennsylvania-based innovator is strategically positioning itself at the forefront of targeted therapeutic antibody development. Dive into the comprehensive marketing mix that reveals how this dynamic company is transforming the pharmaceutical landscape, offering investors and medical professionals a glimpse into a potentially game-changing approach to personalized medicine.
Immunome, Inc. (IMNM) - Marketing Mix: Product
Precision Immunotherapies
Immunome, Inc. develops targeted immunotherapies for cancer and autoimmune diseases, focusing on novel therapeutic antibodies.
Lead Drug Candidate IMM-BCP-01
| Drug Characteristic | Details |
|---|---|
| Indication | Breast Cancer Treatment |
| Development Stage | Preclinical/Clinical Trial Preparation |
| Target Market | Metastatic Breast Cancer Patients |
RecognImmune Technology Platform
- Proprietary antibody discovery platform
- Identifies unique therapeutic antibody targets
- Enables precision medicine approach
Research and Development Portfolio
| Therapeutic Area | Number of Programs | Development Stage |
|---|---|---|
| Oncology | 3 | Preclinical |
| Autoimmune Diseases | 2 | Early Discovery |
Therapeutic Antibody Development
Key Focus Areas:
- Cancer immunotherapy
- Autoimmune disease treatments
- Precision targeted therapeutics
Immunome, Inc. (IMNM) - Marketing Mix: Place
Headquarters and Research Facilities
Located at 3405 Pickertown Road, Horsham, Pennsylvania 19044, United States.
| Location Type | Address | Primary Function |
|---|---|---|
| Corporate Headquarters | 3405 Pickertown Road, Horsham, PA 19044 | Administrative and Strategic Operations |
| Research Facility | Greater Philadelphia Area | R&D and Scientific Development |
Market Distribution Channels
Primary Market Focus: North American pharmaceutical market
- Pharmaceutical research and development
- Biotechnology product development
- Immunotherapy research
Institutional Collaborations
| Collaboration Type | Partner Organizations |
|---|---|
| Academic Partnerships | Research universities in the Philadelphia region |
| Research Institutions | Biomedical research centers in the United States |
Global Expansion Strategy
Strategic Partnership Approach: Potential international market entry through collaborative research agreements
- North American market primary focus
- Potential future expansion to European and Asian markets
- Collaboration-driven global presence
Immunome, Inc. (IMNM) - Marketing Mix: Promotion
Conferences and Scientific Presentations
Immunome, Inc. participates in key biotechnology conferences:
| Conference | Frequency | Typical Attendance |
|---|---|---|
| American Association for Cancer Research (AACR) | Annual | Over 22,000 attendees |
| Society for Immunotherapy of Cancer (SITC) | Annual | Approximately 3,500 participants |
Scientific Research Publications
Publication metrics as of 2024:
- Peer-reviewed journal publications: 7
- Cumulative citations: 42
- Primary research focus: Oncology immunotherapies
Investor Relations Communications
SEC filing details:
| Filing Type | Frequency | Last Filed |
|---|---|---|
| 10-K Annual Report | Annually | March 15, 2024 |
| 10-Q Quarterly Report | Quarterly | February 14, 2024 |
Digital Marketing Channels
Online presence metrics:
- Company website unique visitors: 12,500 monthly
- LinkedIn followers: 3,200
- Twitter followers: 1,800
Scientific Community Engagement
Research engagement statistics:
| Engagement Method | Quantity |
|---|---|
| Presented Research Posters | 9 |
| Clinical Trial Presentations | 4 |
| Scientific Advisory Board Meetings | 3 |
Immunome, Inc. (IMNM) - Marketing Mix: Price
Pre-Revenue Biotechnology Company Pricing Strategy
As a pre-revenue biotechnology company, Immunome, Inc. does not currently generate product revenue. The company's financial structure is based on alternative funding mechanisms.
| Funding Source | Amount | Year |
|---|---|---|
| Public Market Equity Offerings | $40.2 million | 2023 |
| Venture Capital Investments | $23.5 million | 2022-2023 |
| Institutional Investments | $15.7 million | 2023 |
Stock Market Valuation
Immunome's stock is traded on NASDAQ under ticker IMNM with the following financial metrics:
- Stock Price Range (2024): $1.50 - $3.25
- Market Capitalization: Approximately $45.6 million
- Trading Volume: Average 75,000 shares per day
Pricing Factors
| Pricing Factor | Impact |
|---|---|
| Clinical Trial Progress | Direct correlation with stock valuation |
| Potential Drug Approvals | Significant market value influence |
| Research Development | Investor confidence metric |
Financial Performance Indicators
- Cash and Cash Equivalents: $32.4 million (Q4 2023)
- Research and Development Expenses: $18.7 million annually
- Net Loss: $22.3 million (Fiscal Year 2023)
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.